Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)
Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by…{post_date: F d, Y}
Mayo Clinic platform aids clinical decisions
IMC Newsdesk: Mayo Clinic has developed health technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide…{post_date: F d, Y}
Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal
FDA News: Pfizer has entered into a multi-year deal with Anumana — a joint venture between the Mayo Clinic and nference, an electronic health record data company — to develop…{post_date: F d, Y}
Mayo Clinic Launches Two Companies To Support New Remote Monitoring Initiative
Medtech Insight: The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.{post_date: F d, Y}